CY1112517T1 - Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης - Google Patents

Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης

Info

Publication number
CY1112517T1
CY1112517T1 CY20121100144T CY121100144T CY1112517T1 CY 1112517 T1 CY1112517 T1 CY 1112517T1 CY 20121100144 T CY20121100144 T CY 20121100144T CY 121100144 T CY121100144 T CY 121100144T CY 1112517 T1 CY1112517 T1 CY 1112517T1
Authority
CY
Cyprus
Prior art keywords
truladist
modified release
pharmaceutical forms
forms modified
polyglycol
Prior art date
Application number
CY20121100144T
Other languages
Greek (el)
English (en)
Inventor
Pawan Seth
Paul J Maes
Original Assignee
Valeant International (Barbados) Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27765948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant International (Barbados) Srl filed Critical Valeant International (Barbados) Srl
Publication of CY1112517T1 publication Critical patent/CY1112517T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Paints Or Removers (AREA)
CY20121100144T 2002-02-21 2012-02-13 Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης CY1112517T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35785102P 2002-02-21 2002-02-21
EP03743147A EP1476138B8 (en) 2002-02-21 2003-02-21 Modified release formulations of at least one form of tramadol

Publications (1)

Publication Number Publication Date
CY1112517T1 true CY1112517T1 (el) 2015-12-09

Family

ID=27765948

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100144T CY1112517T1 (el) 2002-02-21 2012-02-13 Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης

Country Status (15)

Country Link
US (4) US7780987B2 (enExample)
EP (2) EP1476139B1 (enExample)
JP (3) JP5069395B2 (enExample)
AT (1) ATE536173T1 (enExample)
AU (2) AU2003211145B2 (enExample)
CA (2) CA2476201C (enExample)
CY (1) CY1112517T1 (enExample)
DK (1) DK1476138T3 (enExample)
ES (2) ES2377729T3 (enExample)
MX (2) MXPA04008164A (enExample)
NO (1) NO20043913L (enExample)
NZ (2) NZ535455A (enExample)
PT (1) PT1476138E (enExample)
SI (1) SI1476138T1 (enExample)
WO (2) WO2003072089A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
ES2377729T3 (es) 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Formulaciones de liberación modificada de al menos una forma de tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
US7206632B2 (en) 2003-10-02 2007-04-17 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
US20050074469A1 (en) * 2003-10-03 2005-04-07 Charles Signorino Stable lipophilic emulsions for acrylic coating and method of making
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1809260B1 (en) * 2004-11-08 2013-11-27 Rubicon Research Private Limited Aqueous pharmaceutical coating
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
AU2006269225B2 (en) * 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
CN101242856A (zh) 2005-09-09 2008-08-13 莱博法姆公司 持续药物释放的组合物
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
CZ300698B6 (cs) * 2006-06-16 2009-07-22 Zentiva, A. S. Tableta s obsahem metforminu
US20080031927A1 (en) * 2006-07-11 2008-02-07 Catani Steven J Solid oral dosage vitamin and mineral compositions
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20130064896A1 (en) * 2009-12-29 2013-03-14 Laman Lynn Alani Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JP2018043198A (ja) * 2016-09-15 2018-03-22 トヨタ自動車株式会社 粉粒体混合機
BR112019012171B1 (pt) * 2016-12-15 2021-02-09 Spero Therapeutics, Inc novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil
WO2019143744A1 (en) * 2018-01-16 2019-07-25 Applied Materials, Inc. Metal oxide encapsulated drug compositions and methods of preparing the same
DE102018001601A1 (de) * 2018-03-01 2019-09-05 Mann+Hummel Gmbh Koaleszenzabscheider, insbesondere zur Verwendung in einem Kompressordruckluftsystem, Kompressordruckluftsystem sowie Verwendung eines Koaleszenzabscheiders
KR20220066056A (ko) * 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. 조성물, 제형, 및 인터루킨 제조 및 정제
JP2022546946A (ja) 2019-08-27 2022-11-10 アプライド マテリアルズ インコーポレイテッド 乱用抑止医薬製剤のための気相コーティング技術
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
CA3201497A1 (en) 2020-11-11 2022-05-19 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
CN118215470A (zh) 2021-09-30 2024-06-18 应用材料公司 用于制药应用的低温氧化硅涂层

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097144A (en) * 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63215620A (ja) * 1987-03-03 1988-09-08 Nippon Soda Co Ltd 徐放性製剤
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
JP2700662B2 (ja) * 1988-06-22 1998-01-21 大正製薬株式会社 被覆製剤
DK0386440T3 (da) * 1989-02-11 1992-09-14 Bayer Ag Lægemidler med kontrolleret afgivelse af virksomt stof
US5292522A (en) * 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
WO1991015194A1 (en) 1990-04-11 1991-10-17 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
AU7966694A (en) * 1993-07-21 1996-05-02 University Of Kentucky Research Foundation, The A multicompartment hard capsule with control release properties
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
AU5310898A (en) 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ATE322892T1 (de) * 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
DE19826517B4 (de) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20030153607A1 (en) 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
DE19901686A1 (de) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
IN191482B (enExample) 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
NZ517559A (en) * 1999-08-31 2004-08-27 Gruenenthal Chemie Sustained release pharmaceutical composition containing tramadol saccharinate
SK287684B6 (sk) 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6676966B1 (en) 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
IN192159B (enExample) 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
ITMI20010220A1 (it) 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
CA2441064A1 (en) 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
JP5138856B2 (ja) * 2001-06-20 2013-02-06 武田薬品工業株式会社 錠剤の製造方法
BR0212951A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030118647A1 (en) 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US6667054B2 (en) 2001-12-05 2003-12-23 Bernard Charles Sherman Metformin hydrochloride tablets
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
SI1355633T1 (en) 2001-12-19 2005-06-30 Astrazeneca Ab NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
EP1474123A1 (en) 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Controlled release pharmaceutical formulation containing venlafaxine
JP2003290319A (ja) * 2002-01-30 2003-10-14 Takeda Chem Ind Ltd 錠剤の製造装置
ES2377729T3 (es) * 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Formulaciones de liberación modificada de al menos una forma de tramadol
AU2003225102A1 (en) 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US6902746B2 (en) 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
SE0202353D0 (sv) 2002-08-01 2002-08-01 Astrazeneca Ab New film coating
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20050048118A1 (en) 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US20050025829A1 (en) 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050084531A1 (en) 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications

Also Published As

Publication number Publication date
JP5069395B2 (ja) 2012-11-07
NZ535455A (en) 2009-08-28
US20080274177A1 (en) 2008-11-06
JP2005526047A (ja) 2005-09-02
EP1476138A4 (en) 2008-05-07
JP2005526043A (ja) 2005-09-02
AU2003211146B2 (en) 2007-07-19
CA2476496C (en) 2009-12-15
JP4704685B2 (ja) 2011-06-15
PT1476138E (pt) 2012-02-14
CA2476496A1 (en) 2003-09-04
SI1476138T1 (sl) 2012-07-31
MXPA04008164A (es) 2005-05-17
EP1476138B8 (en) 2012-03-07
EP1476138B1 (en) 2011-12-07
US20040037883A1 (en) 2004-02-26
ES2377729T3 (es) 2012-03-30
JP2010155864A (ja) 2010-07-15
EP1476139A4 (en) 2007-12-26
AU2003211145A1 (en) 2003-09-09
AU2003211145B2 (en) 2007-07-12
MXPA04008100A (es) 2005-06-17
NO20043913L (no) 2004-11-16
AU2003211146A1 (en) 2003-09-09
NZ535456A (en) 2006-08-31
ES2627842T3 (es) 2017-07-31
DK1476138T3 (da) 2012-02-20
WO2003072089A1 (en) 2003-09-04
US20150030675A1 (en) 2015-01-29
CA2476201A1 (en) 2003-09-04
EP1476139B1 (en) 2017-05-17
US20130245154A1 (en) 2013-09-19
EP1476139A1 (en) 2004-11-17
WO2003072025A2 (en) 2003-09-04
WO2003072025A3 (en) 2003-11-06
EP1476138A2 (en) 2004-11-17
US7780987B2 (en) 2010-08-24
CA2476201C (en) 2009-09-01
ATE536173T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
BG106030A (en) Pharmaceutical composition
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
EE200100670A (et) Amiidasendatud imidasokinoliinid
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
SV2002000581A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester ref.pc10754/700005/bb
HUP0401191A2 (hu) Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
BRPI0309651B8 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
IS6439A (is) Samsetningar til að meðhöndla viðnám gegn háþrýstingslyfjum
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
EA200300110A1 (ru) Композиция элетриптана в виде частиц
SE9903995D0 (sv) New combination
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
SE0001916D0 (sv) Novel formulation